1 study found for:    "NJMS" OR "New Jersey Medical School" | Open Studies | "Bronchial Neoplasms"
Show Display Options
Rank Status Study
1 Recruiting Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or In Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
Conditions: Recurrent Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Drug: erlotinib hydrochloride;   Drug: cabozantinib-s-malate;   Other: laboratory biomarker analysis

Indicates status has not been verified in more than two years